EA201890764A1 - Селективные антагонисты nr2b - Google Patents

Селективные антагонисты nr2b

Info

Publication number
EA201890764A1
EA201890764A1 EA201890764A EA201890764A EA201890764A1 EA 201890764 A1 EA201890764 A1 EA 201890764A1 EA 201890764 A EA201890764 A EA 201890764A EA 201890764 A EA201890764 A EA 201890764A EA 201890764 A1 EA201890764 A1 EA 201890764A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nr2b
selective antagonists
formula
compounds according
nmda
Prior art date
Application number
EA201890764A
Other languages
English (en)
Inventor
Имадул Ислам
Сринивасан Тангатирупати
Джайакумар Санкара Варриер
Сринивас Черуку
Пурнима Шетти
Джон Е. Мэйкор
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201890764A1 publication Critical patent/EA201890764A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к соединениям согласно формуле (I) и их фармацевтически приемлемым солям. Соединения согласно формуле (I) представляют собой лиганды для рецептора NR2B N-метил-D-аспартата (NMDA), что делает их применимыми для лечения различных нарушений центральной нервной системы.
EA201890764A 2015-10-14 2016-10-13 Селективные антагонисты nr2b EA201890764A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3309DE2015 2015-10-14
PCT/US2016/056716 WO2017066368A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (1)

Publication Number Publication Date
EA201890764A1 true EA201890764A1 (ru) 2018-09-28

Family

ID=57208377

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890764A EA201890764A1 (ru) 2015-10-14 2016-10-13 Селективные антагонисты nr2b

Country Status (13)

Country Link
US (2) US10501451B2 (ru)
EP (1) EP3362447B1 (ru)
JP (1) JP6843853B2 (ru)
KR (1) KR20180064507A (ru)
CN (1) CN108368101B (ru)
AU (1) AU2016340239A1 (ru)
BR (1) BR112018007181A2 (ru)
CA (1) CA3001894A1 (ru)
EA (1) EA201890764A1 (ru)
ES (1) ES2822830T3 (ru)
IL (1) IL258611A (ru)
MX (1) MX2018004257A (ru)
WO (1) WO2017066368A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001890A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
JP7093469B2 (ja) * 2018-10-17 2022-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用
TWI828779B (zh) * 2018-10-17 2024-01-11 德商百靈佳殷格翰國際股份有限公司 4-吡-2-基甲基-嗎啉衍生物及其作為醫藥之用途
EP3867245B1 (en) * 2018-10-17 2022-12-07 Boehringer Ingelheim International GmbH 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
JP2023551943A (ja) * 2020-12-04 2023-12-13 ノバルティス アーゲー うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン
CN113620896A (zh) * 2021-08-31 2021-11-09 青岛科技大学 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
RU2339630C2 (ru) 2003-06-04 2008-11-27 Мерк Энд Ко., Инк. 3-фторпиперидины в качестве антагонистов nmda/nr2b
CA2541162A1 (en) 2003-10-08 2005-04-21 Pfizer Inc. Fused lactam compounds
EP1736474A4 (en) * 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
CN102933226A (zh) * 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
US20200115370A1 (en) 2020-04-16
EP3362447A1 (en) 2018-08-22
US10501451B2 (en) 2019-12-10
IL258611A (en) 2018-06-28
MX2018004257A (es) 2018-05-16
CA3001894A1 (en) 2017-04-20
BR112018007181A2 (pt) 2018-10-16
EP3362447B1 (en) 2020-08-26
JP2018530582A (ja) 2018-10-18
CN108368101A (zh) 2018-08-03
US10954225B2 (en) 2021-03-23
WO2017066368A1 (en) 2017-04-20
KR20180064507A (ko) 2018-06-14
CN108368101B (zh) 2022-03-15
AU2016340239A1 (en) 2018-05-31
JP6843853B2 (ja) 2021-03-17
US20180312495A1 (en) 2018-11-01
ES2822830T3 (es) 2021-05-05

Similar Documents

Publication Publication Date Title
EA201890764A1 (ru) Селективные антагонисты nr2b
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
NZ737399A (en) Ccr2 modulators
EA201691302A1 (ru) Новые гетероциклические соединения
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
PH12017502237A1 (en) Nuclear receptor modulators
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA201700042A1 (ru) Соединения имидазопиридазина
EA201890800A1 (ru) Соединения и композиции для лечения глазных расстройств
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
EA201691413A1 (ru) Селективные антагонисты nr2b